



Media release

Bern, 3 April 2017 / mk

Guidelines for thyroid disorders in older people outdated

The standard treatment for a mildly underactive thyroid gland is thyroid hormone substitution with tablets. The results of the yet largest study today published in *The New England Journal of Medicine*, however, question the benefits of this practice.

A mildly underactive thyroid gland (subclinical hypothyroidism) is a common condition in older age, affecting up to one-in-ten older men and women. According to current guidelines, nine of every ten women with the condition could receive thyroid hormone tablets, typically levothyroxine, which has become the most prescribed drug in the USA and the third most prescribed drug in the UK. The large 5-year European study TRUST now shows that the common treatment of this condition with levothyroxine provides no apparent benefits, calling for a re-evaluation of the treatment. The study results are presented today at the Endocrine Society meeting (ENDO 2017) in Orlando, USA.

European largest clinical trial for mildly underactive thyroid

A team of researchers from five European Universities have followed 737 older adults with subclinical hypothyroidism to determine if levothyroxine provides them clinical benefits. An underactive thyroid has been linked to various health problems, such as tiredness, circulatory problems, muscle weakness, slowed speed of thinking, and increased blood pressure and weight, but it is also argued that the condition causes little harm. Half of the participants were allocated to a placebo and half to levothyroxine, and followed up for two years. The study found that levothyroxine tablets did effectively restore a normal balance of thyroid function, but did not provide any symptomatic benefits. There was also no improvement of muscle strength, speed of thinking or any effect on body weight or blood pressure.

No worthwhile benefits from levothyroxine

Based on these findings the study team concluded that there is now convincing evidence that older people with a mildly underactive thyroid do not get worthwhile benefits from levothyroxine treatment. Prof. Dr.med. Nicolas Rodondi of Inselspital, Bern University Hospital, and University of Bern, who led the study in Switzerland, concludes: "For more than 20 years we were lacking good evidence about screening and treatment of mildly underactive thyroid, although it is commonly treated in clinical practice. Our aim was to definitively clarify the impact of this screening and the efficacy of subsequent therapy among older adults. Our study that is five times larger than previous ones shows the therapy to provide no apparent benefits for older adults and should therefore no longer be started routinely for this condition."

Study link:

<u>Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism</u>, David Stott, Nicolas Rodondi, Patricia Kearney, Rudi Westendorp, Jacobijn Gussekloo, et al., The New England Journal of Medicine, 3 April 2017.

Captions:

Not every tablet holds a benefit for older patients (Symbolic photography, Tanja Läser).

Media enquiries:

Prof. Dr. med. Nicolas Rodondi, Physician-in-Chief, Department of General Internal Medicine, Inselspital, Bern University Hospital, and Director, Institute of Primary Health Care (BIHAM), University of Bern,

Tel: +41 31 632 41 63, Nicolas. Rodondi @insel.ch.

About the TRUST research project

Thyroid Hormone Replacement for Subclinical Hypo-Thyroidism Trial (TRUST) is a European research project of experts in ageing, general internal medicine, thyroid problems and vascular disease, investigating current treatment practices for people who have a mildly underactive thyroid gland. Specific advice for older patients over 80 will be available next year when TRUST results will be combined with an ongoing trial among over 80s. Prof. David Stott from Scotland has coordinated the study, along with collaborators from Switzerland (lead Prof. Nicolas Rodondi), the Netherlands (lead Prof. Jacobijn Gussekloo), Ireland (lead Prof. Patricia Kearney) and Denmark (lead Prof. Rudi Westendorp). The data handling was performed at the Robertson Centre for Biostatistics at the University of Glasgow (lead Prof. Ian Ford). The study was funded by the European Union and supported by the Swiss National Foundation for the Swiss part. In Switzerland, the recruitment of patients was also greatly helped by 443 GPs with the support of the Institute of Primary Health Care (BIHAM), University of Bern (Prof. Nicolas Rodondi), the Institute of Family Medicine (IUMF) at the University of Lausanne and the Service of Endocrinology, Diabetes and Metabolism (Dr. Tinh-Hai Collet) at CHUV in Lausanne. For more information please visit http://www.trustthyroidtrial.com.